XLV

XLV remains in Stage 2 of its long-term uptrend, trading above the rising 9-, 20-, and 50-day EMAs. The recent minor pullback into the EMA confluence zone was accepted, reinforcing structural support. Despite overbought readings, no exhaustion is evident, aligning with the Stable strategy’s patient approach. Short-term timing is favorable, warranting a Buy Now posture.

• ↑MACD & Momentum turned positive; AroonUp above 70 suggests 77% chance of further gains
• ↑YTD -3.1% but 1-year +14.0%; expense ratio 0.08% undercuts peers
• ↓YTD -3.1% despite 14% last-year gain signals near-term stagnation